At Zeal Bio, Alan Bash recommended shutting down operations when the science failed to show sufficient conviction for investors. This tough but pragmatic decision, made sooner rather than later, was respected by investors as it prevented further capital loss on a non-viable program.

When facing severe financial pressure and a low stock price, a CEO's instinct to protect their team can be the right long-term move. Paul Friedman of Incyte resisted board demands for downsizing, arguing the financial impact would be minimal while the cultural damage would be irreversible, and successfully found alternative funding instead.

The current political and regulatory environment means running a biotech company is no longer just about science and capital. CEOs must now actively engage in policy discussions and lobby legislators to ensure the ecosystem remains favorable for innovation. Ignoring politics is no longer an option.

A company's approach to investor relations—whether it focuses on short-term guidance or long-term strategy—acts as a filtering mechanism. It actively attracts an "audience" of shareholders whose time horizon and values mirror management's, as Warren Buffett noted, shaping the stability of the company's investor base.

Corporate boards are hesitant to invite individuals who are highly outspoken on public platforms like podcasts. This suggests that boards prioritize discretion and avoiding controversy over the potential benefits of a director with a strong public profile, creating a career trade-off for executives.

In the early stages, a biotech CEO's role is primarily scientific leadership and storytelling to attract investors. As the company and market mature, the role shifts. Effective CEOs must then become adaptable strategists, staying true to their core vision while responding to the dynamic industry environment.

Even with strong scientific data, biotech companies struggle for funding because investor capital chases short-term fads like AI. The belief that "good science will attract money" is a utopian myth; leaders must actively navigate fickle market psychology to survive and raise capital.

Beyond scientific knowledge, the most effective biotech CEOs possess a specific set of traits. They must be decisive, maintain ruthless capital discipline (even for small amounts), and consistently demonstrate strategic clarity, especially when facing the immense pressure inherent in the industry.

Voyager's CEO fosters a non-political culture by insisting on transparency. He encourages open debate during meetings but disallows "backdoor" conversations afterward. This process creates a clear window for dissent before demanding alignment and execution from the team.